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Background. The prolonged time course of Huntington’s disease (HD) neurodegeneration increases both the time and cost of
testing potential therapeutic compounds in mammalian models. An alternative is to initially assess the efficacy of compounds
in invertebrate models, reducing time of testing from months to days. Methodology/Principal Findings. We screened
candidate therapeutic compounds that were identified previously in cell culture/animal studies in a C. elegans HD model and
found that two FDA approved drugs, lithium chloride and mithramycin, independently and in combination suppressed HD
neurotoxicity. Aging is a critical contributor to late onset neurodegenerative diseases. Using a genetic strategy and a novel
assay, we demonstrate that lithium chloride and mithramycin remain neuroprotective independent of activity of the forkhead
transcription factor DAF-16, which mediates the effects of the insulin-like signaling pathway on aging. Conclusions/
Significance. These results suggest that pathways involved in polyglutamine-induced degeneration are distinct from specific
aging pathways. The assays presented here will be useful for rapid and inexpensive testing of other potential HD drugs and
elucidating pathways of drug action. Additionally, the neuroprotection conferred by lithium chloride and mithramycin
suggests that these drugs may be useful for polyglutamine disease therapy.
Citation: Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, et al (2007) Identification of Potential Therapeutic Drugs for Huntington’s Disease
using Caenorhabditis elegans. PLoS ONE 2(6): e504. doi:10.1371/journal.pone.0000504
INTRODUCTION
Drug discovery for late onset neurodegenerative diseases is a major
challenge. In large part, the complexity of treating these disorders
results from our insufficient understanding of the contributions of
multiple pathways on disease pathophysiology. Furthermore, since
the pathology of these disorders is often only discernable in aged
populations, testing the therapeutic value of small molecules in
vertebrate disease models requires time consuming and costly
experimental designs. The development of rapid and inexpensive
in vivo assays to evaluate the numerous candidate compounds
identified in high-throughput screens is therefore of paramount
importance.
Invertebrate model organisms such as C. elegans provide an
attractive alternative for prioritizing lead compounds in the early
stages of drug development for age-related diseases [1–3]. C. elegans
has several characteristics that make it ideal for drug testing-
including a short lifecycle, small size and the ease of culturing in
liquid. Furthermore, decades of neurobiological and antiparasitic
drug studies in C. elegans provide a strong foundation for use of this
organism in therapeutic compound identification [1–3].
Huntington’s Disease (HD) is caused by expansion of a poly-
glutamine (polyQ) tract in the huntingtin protein leading to
neurodegeneration that is age and polyQ tract length dependent
[4]. In this study, we use a C. elegans model of polyQ neurotoxicity
in which the N-terminal 171 amino acid fragment of human
huntingtin protein containing an expanded polyglutamine tract
(150Qs) is expressed in neurons. Degeneration and cell death in
this model is dependent on both age and polyglutamine tract
length, recapitulating these aspects of the human disease [4–6].
We tested a collection of compounds that have been previously
described to decrease degeneration in cell culture/animal models
of polyQ toxicity for their ability to protect C. elegans neurons from
the toxic effects of an expanded huntingtin polyglutamine
fragment. We developed, optimized and validated new assays for
use in rapid assessment of drug efficacy using C. elegans HD models.
Of the compounds tested, we found that two FDA approved drugs,
mithramycin (MTR) and lithium chloride (LiCl), reduced polyQ
toxicity in the C. elegans model.
An important determinant of neurodegenerative diseases is the
aging process. However, the mechanistic links between aging and
the cellular pathways leading to neurodegeneration are not well
understood. The forkhead transcription factor DAF-16, which
mediates the effects of the insulin-like signaling pathway on aging,
has been shown to play a role in polyQ aggregation. Mutations
that reduce insulin signaling, derepress DAF-16 leading to an
increase in lifespan and stress resistance [7,8], whereas RNAi
based knockdown of daf-16 accelerates polyQ aggregation and
toxicity [9] suggesting that DAF-16 transcriptional targets not only
promote longevity but also prevent polyQ aggregation. Despite the
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disease, we found that LiCl and MTR protect C. elegans neurons in
the absence of growth and through a daf-16 independent pathway
suggesting that these compounds may target pathways that are
specific to neurodegeneration. Thus, the integration of pharma-
cological and genetic examination of drugs, in C. elegans HD
models that we describe, should accelerate the identification of
interventions for HD along with insight into mechanism of drug
action.
RESULTS
Compound concentration range for screening in C.
elegans: Food Clearance Assay
We tested a collection of compounds that have demonstrated
therapeutic value in either cell culture and/or animal models of
polyQ toxicity for screening in our C. elegans HD models (Table 1).
These candidates represent compounds that may protect against
polyQ toxicity by affecting a variety of cellular pathways. To
efficiently evaluate the effects of these candidates on neurodegen-
eration and neuronal cell death, we first established a systematic
method for selecting optimal drug concentrations to assess in our
C. elegans HD models (see Methods). Compounds were tested in
a dose dilution series in the food clearance assay (Figure 1 and
Figure S1) starting at the highest soluble concentration. Taking
advantage of the short life cycle and the ability of C. elegans to grow
in liquid culture of E. coli, we evaluated compounds by monitoring
the rate at which the E. coli suspension (food source) was
consumed. Each adult is capable of producing hundreds of
progeny that rapidly consume the limited E. coli supply. As a result,
the OD of wells without compound drastically decreases in 3 days.
Any drug that decreases C. elegans growth, survival or fecundity
would result in a dose dependent reduction of the rate at which
food is cleared (consumed) in a well. For example, addition of
5 mM LiCl to the culture showed no effect on food clearance
compared to control animals, whereas animals exposed to 10 mM
or 25 mM LiCl had delayed food clearance (Figure 1B). Visual
inspection confirmed that animals treated with 10 mM and
25 mM LiCl were smaller in size compared to untreated animals
whereas animals treated with 5 mM LiCl were unaffected
(Figure 1C and data not shown). Furthermore, animals exposed
to 50 mM and 100 mM LiCl did not produce progeny over the
time course of the experiment (data not shown), which correlated
with the lack of clearance of the E coli food source. For all
compounds, optimal concentrations for C. elegans were similarly
assessed using the food clearance assay (Table 1). This simple
assay for determining a compound’s concentration range to test in
C. elegans uses a small amount of compound and is amenable to
high-throughput format, making it applicable to any C. elegans drug
study.
Screening neuroprotective compounds in C. elegans
polyQ model
In order to test compounds in an efficient manner, we decided to
reduce the amount of time required to test drug efficacy.
Relatively long assay duration may also be unsuitable for testing
compounds that are unstable under assay conditions. We utilized
a genetic mutant background (pqe-1 loss of function) that
accelerates polyQ mediated neurodegeneration and cell death in
C. elegans from 7 days to 2–3 days. We evaluated neuronal death by
monitoring loss of expression of a GFP reporter construct in the
bilateral ASH sensory neurons in pqe-1;Htn-Q150 animals,
a genetically enhanced model of polyQ toxicity [10] (Figure
S2). In pqe-1;Htn-Q150 animals, the vast majority (.90%) of ASH
neurons undergo cell death in less than three days (Figure S2).
Synchronized pqe-1;Htn-Q150 L1 larvae were treated with and
without drug for three days, then GFP expression was monitored
to assess ASH neuronal viability (Figure 2A). Of the candidates
tested, we identified three protective compounds, mithramycin
(MTR), trichostatin A (TSA) and lithium chloride (LiCl) (Table 1).
All three compounds caused a dose-dependent neuroprotection in
Table 1. Compounds screened in C. elegans polyQ model for neuroprotection.
..................................................................................................................................................
Drugs tested Putative Mechanism
TC 50 Food
clearance (mM)
Conc. Tested
(mM) EC 50 (mM)
Rescue in C.
elegans Activity reported in HD model(s)
LiCl GSK-3b inhibitor 25 10–100 25 Yes Cell culture [31] D. melanogaster
[32]
Mithramycin DNA binding 0.003 0.01–1 0.5 Yes M. musculus [33]
Trichostatin A (TSA) HDAC inhibitor 1 0.16–1 0.16 Yes Cell Culture [34]
C. elegans [14]
S. cerevisiae [35]
SAHA* HDAC inhibitor 2 2 n.a. Yes M. musculus [36]
D. melanogaster [37]
Taxol Cytoskeletal dynamics none 0.4 n.a. no effect Cell culture [38]
Congo Red Aggregation inhibitor 0.5 0.12–0.5 n.a. no effect M. musculus [39]
Cystamine Transglutaminase inhibitor 300 150 n.a. no effect M. musculus [40–42]
D. melanogaster [43]
Cell culture [44]
Budesonide Glucocorticoid receptor
agonist
none 0.8 n.a. no effect Cell culture [45]
Paraquat Free radical generator 3 3 n.a. no effect Negative control [46]
All compounds were tested in pqe-1 enhanced background in the presence of food, E. coli.
n.a. = Not applicable as these compounds were not active.
*SAHA was only tested and found to be active at a single concentration (2 mM). Therefore, an EC50 was not determined.
doi:10.1371/journal.pone.0000504.t001
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PLoS ONE | www.plosone.org 2 June 2007 | Issue 6 | e504the pqe-1 sensitized background (Figure 2B). MTR and TSA
affect transcriptional activity [11,12] and LiCl is a drug used
clinically to treat individuals with bipolar disorders and is
a potential inhibitor of GSKb [13]. Previous studies in C. elegans
demonstrated that TSA reduced polyQ mediated neurodegenera-
tion [14], validating this approach. Htn-Q150 transgene expres-
sion was not altered by drug treatment based on RT-PCR (Figure
S3). Based on these results, we conclude that a genetically
sensitized background (e.g. pqe-1) can be used to dramatically
reduce the amount of time required to accurately assess effects of
drugs on neuronal cell death.
Neuroprotection in an age-dependent C. elegans
polyQ model
To determine if neuroprotection was dependent on pqe-1,w e
tested candidates in the Htn-Q150 only background that exhibits
age-dependent neurodegeneration but no cell death. Late onset
degeneration of ASH sensory neurons was monitored by defects in
dye uptake, a previously described assay [6] (Figure S2).
One limitation due to the prolonged duration (7 days) of the
aging assay is the production of progeny (200–300 per adult) by
the aging animals. Since the progeny grow to adulthood in 3 days,
they are difficult to distinguish from the aged parent by day 7. A
novel genetic strategy was employed to prevent progeny de-
velopment. We crossed Htn-Q150 into a genetic background (pha-
1) in which progeny fail to feed and grow at the restrictive
temperature of 25uC [15]. Introducing pha-1(e2123) to eliminate
progeny development permits the use of liquid cultures and
facilitates any C. elegans aging study (see Methods).
To assay compound efficacy, synchronized pha-1;Htn-Q150 L1
larvae were treated with and without drug for seven days, then
scored for degeneration using the dye-filling assay (Figure 3A).
Introducing the pha-1 mutation had no effect on the dye-filling of
ASH neurons or the polyQ dependent neurodegeneration (data
not shown and Figure S2). LiCl decreased polyQ neurodegen-
eration in a dose dependent manner (Figure 3B) while equivalent
concentrations of sodium chloride (NaCl) had no effect (data not
shown), showing the specificity of LiCl’s effect. Consistent with
previous findings [14], the HDAC inhibitor trichostatin A (TSA)
also suppressed neurodegeneration in the aging assay format
(Figure S4). The confirmation of compound activity in the age
dependent Htn-Q150 model validated the utilization of the pqe-1
sensitized strain as a rapid means of identifying HD therapeutic
compounds.
Dissociating neuroprotection from growth,
development and aging
Since the aging process is a critical but poorly understood
contributor to late onset neurodegenerative diseases [9,16,17],
compounds that affect aging may indirectly affect degeneration.
To distinguish drug effects on neuronal cell death from those on
growth, development and aging rates, we applied two strategies: (i)
we modified our assay format to prevent growth of animals for the
duration of the assay (ii) we genetically altered the well
characterized insulin signaling pathway that affects aging. To
modify our assay, we took advantage of the growth arrest induced
by starvation of L1 stage C. elegans larvae. When embryos hatch in
the absence of food, their development is arrested until food is
available [18,19]. Since starved L1 animals do not grow, the effects
of compounds on neuronal cell death can be evaluated in-
dependent of their effects on growth and development. A further
advantage is that drugs can be tested in the absence of bacteria (E.
coli food source) that could degrade or metabolize compounds
under analysis. Using a starvation assay format (Figure 4A), we
found that ASH neurons continue to undergo neuronal cell death
in pqe-1;Htn-Q150 animals that are growth arrested by the absence
of food (data not shown). This finding suggests that certain
pathways that affect polyQ neurodegeneration are distinct from
pathways that effect growth and development.
We tested LiCl and MTR in this starvation assay format. Both
LiCl and MTR protected ASH neurons of starved animals in
a dose-dependent manner (Figure 4B). Equivalent concentrations
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Figure 1. Concentration of compounds for testing was assessed using a food clearance assay. (A) Flow diagram of the food clearance assay. 20
newly hatched L1 animals were incubated at 25uCi nE. coli at a final OD (A595) of 0.6 in 96 well microtiter plate wells containing varying drug
concentrations. The OD of the microtiter plate was measured daily for 5 days. (B) The OD of E. coli is reported daily for each concentration of LiCl. The
mean OD is calculated for each day from triplicate samples and plotted over time. Error bars represent SEM. Food clearance assays were also
performed on trichostatin A and mithramycin, (Figure S1). (C) Animals treated with no drug and indicated LiCl concentrations. Animals treated with
50 mM or 100 mM LiCl are alive but concentrations above 100 mM LiCl cause death (data not shown). Scale bar is approximately 75 mm.
doi:10.1371/journal.pone.0000504.g001
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demonstrating specificity of the compound’s effect (data not
shown). Using this assay modification, higher concentrations of
compounds that interfere with C. elegans development and growth
were tested in the starvation assay (Figure 1C and Figure 4B).
Therefore, testing drugs in the L1 arrest assay can distinguish
contributions of specific drugs on organismal development and
aging, providing a clearer demonstration of the neuroprotective
properties of compounds.
The insulin signaling pathway, a critical regulator of longevity in
C. elegans, is also a modifier of polyQ toxicity. RNAi mediated
knockdown of daf-16 decreases lifespan and leads to early onset of
polyQ aggregation [9]. To determine if the neuroprotective effects
of LiCl and MTR are dependent on components of the insulin
signaling pathway, we crossed a daf-16 null mutation into pqe-
1;Htn-Q150 animals and tested the effects of LiCl and MTR on
neuronal cell death in the starvation assay. We found that both
compounds remained neuroprotective in the daf-16 mutant
animals in a dose dependent manner (Figure 4C), suggesting
that LiCl and MTR suppress polyQ mediated neuronal cell death
independent of DAF-16 activity. The dissociation of the
neuroprotective effects of compounds from growth and specific
aging pathways allows a mechanistic classification of therapeutic
compounds.
Combinatorial effects of LiCl and MTR
A number of therapies for complex diseases use combinations of
drugs that allow targeting of multiple mechanisms and allow
therapeutic efficacy at lower compound concentrations, limiting
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Figure 2. LiCl, TSA, and MTR decrease polyQ mediated ASH neuronal
death. (A) Flow diagram of the sensitized assay. 20–30 synchronized
pqe-1;Htn-Q150 L1s per well were incubated at 15uC in S medium with
E. coli at an OD (A595) of 0.6 and varying concentrations of compound to
a total volume of 60 ml. Animals were grown in the presence of
compound for 3 days. ASH neuron survival was evaluated by the
presence or absence of GFP expression. (B–D) LiCl, TSA and MTR
increased ASH neuron survival in the pqe-1;Htn-Q150 animals in the
presence of E. coli. ASH neuron survival was evaluated by the presence
or absence of GFP expression on day 3. 100 neurons were scored for
each trial; mean percentage of 3 different trials6SEM is shown.
p,0.0001 for 25 mM LiCl. p=.037 for 0.5 mM MTR; p,0.0001 for 1 mM
MTR. p=0.0082 for 165 mM TSA; p=0.005 for 330 mM TSA.
doi:10.1371/journal.pone.0000504.g002
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elegans assay in drug combinatorial studies by testing LiCl in
combination with MTR on C. elegans polyQ toxicity in the
starvation assay. Combining 25 mM LiCl and 0.5 mM mithra-
mycin in the starvation assay format increased ASH neuron
survival compared to the protection afforded by either compound
alone (Figure 4D).
DISCUSSION
In this study, we have devised strategies for efficiently assessing
therapeutic efficacy of compounds in C. elegans HD models
(Figure 5). Our methods exploit the strengths of C. elegans model
for drug discovery, including convenient and precise visualization
of live neurons, small-scale liquid cultures that significantly reduce
the amount of drug required for testing as well as genetic
approaches to implicate specific cellular pathways in a compound’s
mechanism of action. These assays could be utilized for
prioritizing the large numbers of hits already identified by high-
throughput screens for HD and other polyQ diseases [20–23].
The normal aging process is intricately linked to late onset
neurodegenerative diseases. However, the influence of aging on
cellular events that impact neurodegeneration is unclear. To
dissect the interplay of pathways involved in neurodegeneration
from those involved in aging, we combined genetic manipulations
with a novel assay that utilizes growth-arrested animals. Our
studies demonstrate that LiCl and MTR exert their neuroprotec-
tion in a daf-16 independent manner. However, starvation of
animals may activate additional stress responsive transcription
factors such as heat shock factor (HSF1). HSF1 regulates the heat
shock response and also influences longevity [17,24,25]. Further-
more, HSF1 RNAi enhances polyQ aggregation [26] raising the
possibility that HSF1 or other stress activated pathways may
function as molecular targets of these compounds. However, the
fact that neurons continue to die under conditions of starvation
suggests that the stress responses induced by starvation are
insufficient to abrogate the neurodegenerative process. Thus, the
combination of strategies outlined in the study allows the
separation of drug effects on neurodegeneration from those on
growth and stress related aging pathways.
Though we focus on neurodegeneration in HD models, similar
strategies may apply to other age dependent phenotypic readouts.
For example, deletion of the C. elegans dystrophin gene, the
homolog of a gene involved in Duchenne’s Muscular Dystrophy,
in combination with a second mutation in the myogenic factor
MyoD leads to progressive muscle degeneration [27,28]. Using the
strategies described in this study, the protective effect of
A
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These C. elegans disease models should be valuable tools for rapid
identification of potential therapeutic compounds for aging related
human diseases and cellular pathway elucidation of any
compounds that are active in these models.
MATERIALS AND METHODS
Strains
C. elegans N2[wild-type] and GE24[pha-1(e2123)], E. coli food
sources OP50 and HB101 (OP50 for compound efficacy and aging
assays and HB101 for sensitized and food clearance assays) were
obtained from the Caenorhabditis elegans Genetics Center. Htn-
Q150(rtIs11) expressing strains with and without pqe-1(rt13) were
previously described [6,10]. daf-16(mgDf47) was crossed into pqe-
1(rt13) mutant strain expressing Htn-Q150(rtIs11) marked with dpy-
11(e224). All mutations were homozygous in the final strain for
analysis. All strains were cultivated on nematode growth media
(NGM) plates at 15uC [29].
Food Preparation
E. coli were grown overnight at 37uC in Luria broth (LB) media,
pelleted by centrifugation, frozen at 270uC, and then resuspended
at a final OD of 0.5 (595 nm) for the aging assay or an OD of 6.6
in nematode S-medium [29] (supplemented with 1006 strepto-
mycin/penicillin (Invitrogen, #15140-122) and nystatin (Sigma,
#N1638)) for all other food based assays. Note the lower OD
(,0.6) in plates was due to a decreased path length of the 60 ml
final suspension, in a well, compared to a 1 cm path length in
a spectrophotometer.
Compound Preparation
All compounds were purchased from Sigma (St. Louis, MO). Stock
solution of 1 M lithium chloride (LiCl) in water, 10 mM
mithramycin (MTR) in PBS and 5 mg/ml trichostatin A (TSA)
in DMSO were stored at room temperature (LiCl), 10–14 days at
4uC (MTR) and at 220uC (TSA). Compounds were diluted into
E. coli suspension or S-medium (starvation assay) to the desired
concentrations. 1 ml of the final mixture was added per well of
a 24-well polystyrene plate for the aging assay. For the remaining
assays, 50 ml of the final mixture was added per well in a 96-well
polystyrene plate.
C. elegans Preparation
We used newly hatched C. elegans, collected as L1 larvae at 15uC.
Specifically, adults were lysed, fertilized eggs were collected by
hypochlorite treatment of gravid adults and suspended in S-
medium for 24–30 hours at 15uC and L1 larvae were allowed to
hatch overnight in the absence of food [29]. pha-1(e2123) is
a temperature sensitive loss of function allele that affects normal
pharyngeal development [15]. A normal pharynx forms at the
permissive temperature of 15uC in newly hatched L1 animals
while the pharynx fails to develop in pha-1(e2123) animals hatched
at 25uC. C. elegans L1 animals do not initiate growth in the absence
of food, resulting in a synchronous population of arrested L1
animals. Introduction of a food source (E. coli) results in growth;
animals become adult hermaphrodites within 48 hours at 25uC.
This L1 growth arrest and recovery provides an efficient means of
collecting large numbers of synchronized animals for assays.
Food Clearance Assay
The effect of compounds on C. elegans physiology is monitored by
the rate at which the E. coli food suspension was consumed, as
a read out for C. elegans growth, survival or fecundity.
Approximately 20–30 L1 synchronized animals per 10 mlo fS -
media were added to an E. coli suspension. Microtiter plates
containing animals and drugs were incubated at 25uC. The
absorbance (OD 595nm) was measured daily using a Vmax
Kinetic microplate reader (Molecular Devices). We used N2
animals when determining compound concentration. Introduction
of pha-1(e2123), pqe-1(rt13), daf-16(mgDf47) or Htn-Q150(rtIs11)
had no effect on overall growth or health of the animal compared
to N2 in the presence of drug at assay temperatures.
Scoring Degeneration and Cell Death
At time points indicated, animals were collected by centrifugation,
washed in S-media and immobilized with 5 mM sodium azide on
a 2% agarose pad. GFP fluorescence was scored using an
Axioplan2 fluorescence microscope (n=100 ASH neurons). For
the aging assay, degeneration was assessed by dye-filling [6].
Animals were incubated for 2 hours in 1,19-dioctadecyl-3,3,39,39-
tetramethylindodicarbocyanine perchlorate (DiD) (Molecular
Probes) and immobilized as above for scoring ASH dye filling
(n=50 ASH neurons). To determine statistical significance, we
compared the results from parallel experiments using 262
contingency tables comparing the number of GFP+ and GFP-
neurons in control vs. specific concentrations of a compound. We
determined the statistical significance using a Fisher’s exact test for
each of the three independent experiments and reported the
Potential HD therapeutics
determine optimal 
drug concentrations
food clearance assay
 identify hits 
 confirm drug efficacy 
   in HD alone model
exclude drug effects on
growth/development
daf16-/-
exclude effects of drugs
on (insulin) aging pathway
pqe-1 enhanced 
HD model
aging assay
starvation assay
Figure 5. Schematic Diagram of Compound Testing Strategy. (1) A
range of concentrations for each compound for testing in C. elegans
was established using the food clearance assay. (2) The protective
effects of compounds on polyglutamine neurodegeneration and cell
death were assessed in pqe-1;Htn-Q150 animals treated with com-
pounds for 3 days. (3) To determine if neuroprotective effects of
compounds were dependent on pqe-1, compounds were retested in
animals expressing Htn-Q150 for 7 days. (4) To distinguish drug effects
on neuronal cell death versus effects on growth and/or development,
synchronized pqe-1;Htn-Q150 L1 animals were incubated in the
presence of drugs without food for 2 days. (5) The neuroprotective
effects of compounds on the aging process can be tested by
introducing mutations (daf-16) in components of specific aging-related
(insulin signaling) pathways.
doi:10.1371/journal.pone.0000504.g005
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In Figure 4d, Bliss Independence was assessed [30]. Neuronal
survival was converted to a fractional scale with no drug treatment
(17%) arbitrarily set to 0 and 100% survival set to 1. Survival for
each drug and the combination was converted to a fraction and the
Bliss Independence score was calculated as C=A+B2AB, where A
and B are the fractional survival for LiCl and MTR and C is the
predicted effect for the combination. The difference between C and
the actual value (fractional) was calculated to assess synergy. LiCl
had a fractional survival of 0.22, MTR 0.19 and the combination
0.51. The expected value for the combination was 0.37. The excess
0.14 was a measure of synergy.
Quantitative Real Time PCR Analysis
qRT-PCR analyses were carried out using the SYBR Green
method (BioRad) and the SmartCycler 1600 System by Cepheid
Innovation. Total RNA was extracted using Trizol (Invitrogen),
DNase treated (Ambion), followed by cDNA synthesis (BioRad)
according to manufacturer’s instructions. The primers used for
amplification of the actin gene, act-1, are 59-atcaccgctcttgccccatc-
39 (for) and 59-ggccggactcgtcgtattcttg-39 (rev). Primers for Htn
transgene were previously described [3].
SUPPORTING INFORMATION
Figure S1 Concentration of compounds for testing in C. elegans
was assessed using a food clearance assay. The OD of E. coli is
reported daily for each concentration of TSA (A) and MTR (B).
The mean OD is calculated for each day from triplicate samples
and plotted over time.
Found at: doi:10.1371/journal.pone.0000504.s001 (1.17 MB EPS)
Figure S2 C. elegans model of polyQ neurodegeneration and cell
death [6,10]. (A) An N-terminal fragment of human huntingtin
with 150 glutamines (Htn-Q150) was expressed in C. elegans ASH
neurons as previously described [6]. (B) A GFP reporter expressed
in the ASH neurons was used to assess cell death; loss of GFP
expression in ASH neurons indicates cell death as shown here in
young pqe-1;Htn-Q150 animals (bottom panel). (C) The ASH
neuron and 5 other sensory neurons in Htn-Q150 young (top
panel) or aged (bottom panel) animals were visualized by dye
filling. Sensory endings of ASH neurons expressing Htn-Q150
degenerate in aged animals and fail to take up dye (bottom panel).
(D) ASH neuronal survival decreases dramatically over time based
on GFP fluorescence. By day 3, 75% of ASH neurons are dead in
pqe-1;Htn-Q150 animals. Error bars represent SEM. Scale bar is
approximately 20 nm. (E) Only 21% of ASH neurons remain
intact in aged (7 day) pha-1 animals expressing Htn-Q150 raised at
25uC compared to young (3 day) animals based on dye filling.
Found at: doi:10.1371/journal.pone.0000504.s002 (2.94 MB EPS)
Figure S3 HtnQ150 transgene levels are not decreased in the
presence of LiCl or MTR. Relative HtnQ150 transgene levels
were determined using the DDCt method and normalized to an
act-1 control. Results are from two independent RNA collections
from untreated animals (C) and animals treated with 25 mM LiCl
or 0.5 mM MTR in the starved assay format for 24 hours at 15uC.
The error bars indicate the standard deviation from two replicates
of qRT-PCR experiments comparing untreated and drug treated
samples.
Found at: doi:10.1371/journal.pone.0000504.s003 (0.63 MB EPS)
Figure S4 HDAC inhibitor trichostatin A (TSA) decreases
polyQ toxicity measuring ASH neurodegeneration or neuronal
death. At least three trials for each efficacy assay were performed.
Representative experiments are depicted. (A) TSA decreases
polyQ toxicity in a pqe-1 independent manner in pha-1;Htn-Q150
aged animals. 30 synchronized pha-1;Htn-Q150 L1s per well were
incubated at 25uC in S medium with E. coli at an OD at A595 of
0.5 with varying concentrations of TSA to a total volume of 1 ml.
On day 7, animals were collected, dye filled and 100 neurons were
scored for degeneration. (B) TSA increases neuronal survival in the
absence of growth using the starvation assay. 50 synchronized pqe-
1;Htn-Q150 L1s per well were incubated at 25uC in S medium
with varying concentrations of TSA to a total volume of 60 ml. On
day 2, the survival of 100 ASH neurons was evaluated by the
presence or absence of GFP. Animals were treated with final
concentration of TSA or vehicle (2% DMSO).
Found at: doi:10.1371/journal.pone.0000504.s004 (0.66 MB EPS)
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